Proliferation and motility of HaCaT keratinocyte derivatives is enhanced by fibroblast nemosis.
The role of paracrine tumor-stroma regulation in the progression of cancer is under intense investigation. Activated fibroblasts are key components of the tumor microenvironment providing the soluble factors mediating the regulation. Nemosis is an experimental model to study these parameters: formation of a multicellular spheroid activates fibroblasts and leads to increased production of soluble factors involved in the promotion of growth and motility. Role of nemosis was investigated in the tumorigenesis of HaCaT derivatives representing skin carcinoma progression. Conditioned medium from fibroblast spheroids increased proliferation rate of HaCaT derivatives. Expression of proliferation marker Ki-67 increased significantly in benign A5 and low-grade malignant II-4 cells, but did not further increase in the metastatic RT3 cells. Expression of p63, keratinocyte stem cell marker linked to cancer progression, was augmented by medium from nemotic fibroblasts; this increase was also seen in RT3 cells. Scratch-wound healing of the keratinocytes was enhanced in response to fibroblast nemosis. Neutralizing antibodies against growth factors inhibited wound healing to some extent; the response varied between benign and malignant keratinocytes. Migration and invasion were enhanced by conditioned medium from nemotic fibroblasts in benign and low-grade malignant cells. RT3 keratinocyte migration was further augmented, but invasion was not, indicating their intrinsic capacity to invade. Our data demonstrate that fibroblast nemosis increases proliferation and motility of HaCaT keratinocyte derivatives, and thus nemosis can be used as a model to study the role of soluble factors secreted by fibroblasts in tumor progression.
Räsänen
Kati
K
Haartman Institute, POB 21, FI-00014 University of Helsinki, Finland.
Vaheri
Antti
A
D002460:Cell Line; D002465:Cell Movement / Q000502:physiology*; D049109:Cell Proliferation; D002633:Chemotaxis / Q000502:physiology; D003094:Collagen; D024042:Collagen Type I; D017077:Culture Media, Conditioned; D004338:Drug Combinations; D005347:Fibroblasts / Q000502:physiology; D006801:Humans; D015603:Keratinocytes / Q000166:cytology* / Q000502:physiology*; D019394:Ki-67 Antigen / Q000378:metabolism; D007797:Laminin; D019899:Paracrine Communication / Q000502:physiology; D011509:Proteoglycans; D012878:Skin Neoplasms / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D015534:Trans-Activators / Q000378:metabolism; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins / Q000378:metabolism; D014945:Wound Healing / Q000502:physiology
D024042:Collagen Type I; D017077:Culture Media, Conditioned; D004338:Drug Combinations; D019394:Ki-67 Antigen; D007797:Laminin; D011509:Proteoglycans; C115051:TP63 protein, human; D015534:Trans-Activators; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins; C059485:matrigel; D003094:Collagen